Sonablate develops intelligent, image-guided therapeutic ultrasound technologies and related platforms including high-intensity focused ultrasound (HIFU), low-intensity focused ultrasound (LIFU), low-output focused ultrasound (LOFU), Sonatherm, and SonaTripsy. Its technologies target applications such as prostate tissue ablation, oncology, neuromodulation, cardiovascular disease, and women’s health. The company holds regulatory approvals in more than 50 countries worldwide. Led by CEO Richard Yang and based in Charlotte, NC, Sonablate plans to use new funding to expand global commercialization and adoption, with specific initiatives in the MENA region and potential regional assembly and manufacturing in Saudi Arabia. The recent $200M raise reflects its current financial infusion to support those expansion plans.

Total raised

$200M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026